User profiles for M. Ingelman-Sundberg

Magnus Ingelman-Sundberg

Karolinska Institutet
Verified email at ki.se
Cited by 59764

[HTML][HTML] Dietary long-chain n− 3 fatty acids for the prevention of cancer: a review of potential mechanisms

SC Larsson, M Kumlin, M Ingelman-Sundberg… - The American journal of …, 2004 - Elsevier
Increasing evidence from animal and in vitro studies indicates that n−3 fatty acids, especially
the long-chain polyunsaturated fatty acids eicosapentaenoic acid and docosahexaenoic …

Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity

M Ingelman-Sundberg - The pharmacogenomics journal, 2005 - nature.com
… several different DNA samples by XbaI RFLP using a lower density of the agarose gel and
found some samples which we thought had uncleaved DNA (see Ingelman-Sundberg 25 for …

Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects

M Ingelman-Sundberg, SC Sim, A Gomez… - Pharmacology & …, 2007 - Elsevier
The polymorphic nature of the cytochrome P450 (CYP) genes affects individual drug response
and adverse reactions to a great extent. This variation includes copy number variants (…

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

…, L Bertilsson, M IngelmanSundberg - Clinical …, 2006 - Wiley Online Library
Background and Objective Many drugs, including proton pump inhibitors and certain
antidepressants, are metabolized by the polymorphic cytochrome P450 (CYP) 2C19 enzyme. A …

Metabolic gene polymorphism frequencies in control populations

…, A Hirvonen, LL Hsieh, M Ingelman-Sundberg… - … Biomarkers & Prevention, 2001 - AACR
Using the International Project on Genetic Susceptibility to Environmental Carcinogens (GSEC)
database containing information on over 15,000 control (noncancer) subjects, the allele …

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.

…, F Sjöqvist, M Ingelman-Sundberg - Proceedings of the …, 1993 - National Acad Sciences
Deficient hydroxylation of debrisoquine is an autosomal recessive trait that affects approximately
7% of the Caucasian population. These individuals (poor metabolizers) carry deficient …

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

…, VHM Deneer, M Dupui, M Ingelman-Sundberg… - The Lancet, 2023 - thelancet.com
Background The benefit of pharmacogenetic testing before starting drug therapy has been
well documented for several single gene–drug combinations. However, the clinical utility of a …

Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis

…, GC Farrell, P Hall, M Ingelman-Sundberg… - Hepatology, 1998 - journals.lww.com
… Persson JO, Terelius Y, Ingelman-Sundberg M. Cytochrome P450 dependent formation of
reactive oxygen radicals: isoenzyme-specific inhibition of P450 mediated reduction of oxygen …

Pharmacogenomics and individualized drug therapy

M Eichelbaum, M Ingelman-Sundberg… - Annu. Rev …, 2006 - annualreviews.org
Pharmacogenetics deals with inherited differences in the response to drugs. The best-recognized
examples are genetic polymorphisms of drug-metabolizing enzymes, which affect …

Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment

M Ingelman-Sundberg, M Oscarson… - Trends in pharmacological …, 1999 - cell.com
Approximately 40% of human P450-dependent drug metabolism is carried out by polymorphic
enzymes, which can cause abolished, quantitatively or qualitatively altered or enhanced …